Organigram Global Inc. (OGI)
| Market Cap | 152.47M +9.9% |
| Revenue (ttm) | 196.43M +41.3% |
| Net Income | -18.06M |
| EPS | -0.13 |
| Shares Out | 131.57M |
| PE Ratio | n/a |
| Forward PE | 17.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,486 |
| Open | 1.080 |
| Previous Close | 1.070 |
| Day's Range | 1.060 - 1.140 |
| 52-Week Range | 1.040 - 2.240 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 3.26 (+185.97%) |
| Earnings Date | May 12, 2026 |
About OGI
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dr... [Read more]
Financial Performance
In fiscal year 2025, Organigram Global's revenue was 259.18 million, an increase of 62.15% compared to the previous year's 159.84 million. Losses were -24.76 million, -45.51% less than in 2024.
Financial numbers in CAD Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OGI stock is "Buy." The 12-month stock price target is $3.26, which is an increase of 185.97% from the latest price.
News
Organigram Global Inc (OGI) Q2 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...
Organigram Global Inc (OGI) Q2 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities
Organigram Global Q2 Earnings Call Highlights
Organigram Global NASDAQ: OGI reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market...
Organigram Global Earnings Call Transcript: Q2 2026
Q2 fiscal 2026 saw revenue and margin declines due to operational issues and market softness, but remediation efforts and the Sanity Group acquisition are expected to drive stronger performance in the second half. Guidance for fiscal 2026 projects net revenue above CAD 350 million and improved profitability.
Organigram Global Earnings release: Q2 2026
Organigram Global released its Q2 2026 earnings on May 12, 2026, summarizing the period's financial results.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Slides: Q2 2026
Organigram Global has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
Organigram Global Earnings Call Transcript: Q2 2026
Q2 fiscal 2026 saw revenue and margin declines due to operational issues and market softness, but remediation efforts and the Sanity Group acquisition are expected to drive stronger performance in the second half. Guidance for fiscal 2026 projects net revenue above CAD 350 million and improved profitability.
Organigram Global Earnings release: Q2 2026
Organigram Global released its Q2 2026 earnings on May 12, 2026, summarizing the period's financial results.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Slides: Q2 2026
Organigram Global has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
OGI Reports Q2 Financials with Adjusted EBITDA Decline
OGI Reports Q2 Financials with Adjusted EBITDA Decline
OGI Forecasts Strong FY26 Adjusted EBITDA and Low Capital Expenditures
OGI Forecasts Strong FY26 Adjusted EBITDA and Low Capital Expenditures
Options Volatility and Implied Earnings Moves Today, May 12, 2026
Today, several major companies are expected to report earnings: Lineage Therap (LCTX), Achieve Life Sciences (ACHV), Zebra Tech (ZBRA), Organigram Global (OGI), Lithium Argentina (LAR), GrowGeneration...
Organigram Reports Second Quarter Fiscal 2026 Results
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the se...
Organigram (OGI) Set to Release Q2 FY2026 Earnings Report
Organigram (OGI) Set to Release Q2 FY2026 Earnings Report
Organigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings result...
Organigram (OGI) Completes Acquisition of Sanity Group
Organigram (OGI) Completes Acquisition of Sanity Group
Organigram closes acquisition of Sanity Group
Organigram (OGI) Global and Sanity Group jointly announced the successful closing of Organigram’s previously announced acquisition of Sanity Group, pursuant to the terms of a share purchase agreement ...
Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities
TORONTO & BERLIN--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) and Sanity Group GmbH (“Sanity” or “Sanity Group”) jointly announced the successful ...
Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the ...
Organigram (OGI) Gains Support for Sanity Group Acquisition
Organigram (OGI) Gains Support for Sanity Group Acquisition
ISS urges Organigram shareholders to vote for Sanity Group acquisition
Organigram (OGI) is pleased to announce that Institutional Shareholder Services has recommended that holders of common shares of Organigram vote FOR the ordinary resolution to approve the indirect acq...
Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that Institutional Sharehold...